Dendreon Planning To Launch DACS Stem Cell Separator In Six Months
This article was originally published in The Gray Sheet
Executive Summary
Dendreon is seeking a corporate partner to assist in marketing its DACS stem cell device for debulking and enriching hematopoietic stem cells for reconstitution of immune systems of patients undergoing chemotherapy.
You may also be interested in...
First HCFA Coverage Panel To Review Stem Cell Transplantation
High dose chemotherapy and stem cell transplantation combination treatment for multiple myeloma will be reviewed Sept. 15-16 by the Health Care Financing Administration Medicare Coverage Advisory Committee's drugs, biologics and therapeutics panel, an Aug. 13 Federal Register notice states.
First HCFA Coverage Panel To Review Stem Cell Transplantation
High dose chemotherapy and stem cell transplantation combination treatment for multiple myeloma will be reviewed Sept. 15-16 by the Health Care Financing Administration Medicare Coverage Advisory Committee's drugs, biologics and therapeutics panel, an Aug. 13 Federal Register notice states.
Nexell Planning To Seek Labeling Expansion For Isolex 300i In 2001
Nexell Therapeutics plans to file two premarket approval applications in the second half of 2001 to expand labeling for its Isolex 300i magnetic cell selection system, which gained FDA approval July 6.